Antiretroviral News and Research

RSS

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.

15 Apr 2014

Federal district court enforces settlement between Mylan and Endo Pharmaceuticals on generic FROVA

Mylan Inc. today confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for Frovatriptan Succinate Tablets, 2.5 mg.

11 Apr 2014

Added benefit of antiviral drug combination in treatment of HIV-1 patients is not proven

The German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed the antiviral drug combination rilpivirine/emtricitabine/tenofovir. In early 2012, the combination was approved for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) who have not received previous antiretroviral treatment.

8 Apr 2014

ABL enters into licensing agreement with CRP-Santé for COMET software

Advanced Biological Laboratories (ABL) S.A., a Luxembourg-based company today announced that it has entered into an exclusive worldwide licensing agreement with CRP-Santé, a Luxembourg-based public research center active in the field of clinically oriented biomedical research, for its COMET (COntext-based Modeling for Expeditious Typing) software, a tool designed to rapidly analyze and optimally subtype large genetic data sets arising from epidemiological or antiretroviral resistance in the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) fields.

2 Apr 2014

Teva granted certiorari petition related to Mylan's ANDA for Copaxone

Mylan Inc. announced that today the Supreme Court of the United States granted certiorari in Mylan's patent litigation against Teva relating to Mylan's Abbreviated New Drug Application (ANDA) for glatiramer acetate (Copaxone).

1 Apr 2014

Men with long-term HIV infections at higher risk of developing plaque in their coronary arteries

Men with long-term HIV infections are at higher risk than uninfected men of developing plaque in their coronary arteries, regardless of their other risk factors for coronary artery disease, according to results of a study led by Johns Hopkins researchers. A report on the research appears in the April 1 issue of Annals of Internal Medicine.

1 Apr 2014

Researchers find good bacteria that protect women from HIV infection

Researchers at the University of Texas Medical Branch at Galveston by growing vaginal skin cells outside the body and studying the way they interact with "good and bad" bacteria, think they may be able to better identify the good bacteria that protect women from HIV infection and other sexually transmitted infections.

28 Mar 2014

Jury returns verdict in favor of Mylan in breach of contract case against GSK

Mylan Inc. today announced that, after a trial in the United States District Court for the District of New Jersey, a jury returned a verdict in favor of Mylan in its breach of contract lawsuit against GlaxoSmithKline (GSK) relating to Paroxetine Hydrochloride Extended-release (ER) Tablets.

27 Mar 2014

Drugs fail to "wake up" dormant reservoirs of HIV inside immune system T cells

Scientists at Johns Hopkins report that compounds they hoped would "wake up" dormant reservoirs of HIV inside immune system T cells - a strategy designed to reverse latency and make the cells vulnerable to destruction - have failed to do so in laboratory tests of such white blood cells taken directly from patients infected with HIV.

24 Mar 2014

Patients with both HIV and hepatitis C have 80% higher rates of serious liver disease

A new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania has found that the risk of hepatitis C-associated serious liver disease persists in HIV patients otherwise benefitting from antiretroviral therapy (ART) to treat HIV.

18 Mar 2014

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck, known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor.

5 Mar 2014

Stock-outs of ARV drugs in Central African Republic impact health of HIV-infected people

According to Pierre-Marie David of the University of Montreal's Faculty of Pharmacy, stock-outs of antiretroviral (ARV) drugs in recent years in the Central African Republic have had a dramatic impact on the health of HIV-infected people.

5 Mar 2014

Novel HIV prevention products for women demonstrate safety in clinical studies

Two early clinical studies of novel HIV prevention products for women - the first combination antiretroviral (ARV) vaginal ring and a vaginal film - show the products to be safe and open the door to product improvements that could expand options for women-initiated prevention tools. The results of both studies were presented today at the 21st Conference on Retroviruses and Opportunistic Infections.

5 Mar 2014

Women using DMPA injection more likely to acquire HIV than women using NET-EN

Women who used an injectable contraceptive called DMPA were more likely to acquire HIV than women using a similar product called NET-EN, according to a secondary analysis of data from a large HIV prevention trial called VOICE, researchers from the National Institutes of Health-funded Microbicide Trials Network reported today at the 21st Conference on Retroviruses and Opportunistic Infections in Boston.

5 Mar 2014

Study: Combination intervention completely eliminates HIV transmission

A computer model has created the most effective formula for reducing the spread of HIV among drug users in New York City over the next 25 years.

5 Mar 2014

Researchers examine how ACA could affect Americans living with HIV/AIDS

A series of papers in the March issue of Health Affairs examines how the Affordable Care Act could affect two sectors of the most vulnerable Americans - those living with HIV/AIDS and people who have recently cycled through jail.

4 Mar 2014

Study: Rate of mother to child HIV transmission is at an all-time low in the UK

The rate of mother to child HIV transmission is at an all-time low in the UK, according to a paper published today in the journal AIDS.

26 Feb 2014

Professor receives $17M NIH grant to support IMPAACT Network

Grace Aldrovandi, MD, CM, principal investigator at The Saban Research Institute of Children's Hospital Los Angeles, has been awarded $17 million by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

20 Feb 2014

Chronic intake of marijuana protects critical immune tissue from damaging effects of HIV infection

New evidence that chronic intake of THC, the primary psychoactive ingredient in marijuana, can protect critical immune tissue in the gut from the damaging effects of HIV infection is reported in AIDS Research and Human Retroviruses, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

19 Feb 2014

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).

19 Feb 2014

Antiretroviral News and Research

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Federal district court enforces settlement between Mylan and Endo Pharmaceuticals on generic FROVA

Added benefit of antiviral drug combination in treatment of HIV-1 patients is not proven

ABL enters into licensing agreement with CRP-Santé for COMET software

Teva granted certiorari petition related to Mylan's ANDA for Copaxone

Men with long-term HIV infections at higher risk of developing plaque in their coronary arteries

Researchers find good bacteria that protect women from HIV infection

Jury returns verdict in favor of Mylan in breach of contract case against GSK

Drugs fail to "wake up" dormant reservoirs of HIV inside immune system T cells

Patients with both HIV and hepatitis C have 80% higher rates of serious liver disease

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Stock-outs of ARV drugs in Central African Republic impact health of HIV-infected people

Novel HIV prevention products for women demonstrate safety in clinical studies

Women using DMPA injection more likely to acquire HIV than women using NET-EN

Study: Combination intervention completely eliminates HIV transmission

Researchers examine how ACA could affect Americans living with HIV/AIDS

Study: Rate of mother to child HIV transmission is at an all-time low in the UK

Professor receives $17M NIH grant to support IMPAACT Network

Chronic intake of marijuana protects critical immune tissue from damaging effects of HIV infection

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News